COMP <GO>
ULBI vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
Ultralife Corporation (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ULBI 3
— TMO 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TMO
LAST: $15.62 (+0.06%) • MKT CAP: $260.3M
roic
-2.80%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ULBI VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ULBI | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 24.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -2.80% | 9.30% | -12.10 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.73% | 2.40% | +0.33 | ULBI | /fcf-yield <GO> |
| Operating Margin | -3.10% | 17.40% | -20.50 | TMO | /operating-margins <GO> |
| Net Profit Margin | -3.10% | 15.10% | -18.20 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 16.20% | 3.90% | +12.30 | ULBI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.71 | 4.50 | -1.79 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 93.4 | 62.9 | +30.53 | ULBI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 36.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $260.3M | $262.22B | -$261.96B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ULBI REV | TMO REV | ULBI GROSS % | TMO GROSS % | ULBI FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $191.2M | $44.56B | 24.1% | — | $7.1M | $6.29B |
| FY 2024 | $164.5M | $42.88B | 25.7% | — | $14.7M | $7.27B |
| FY 2023 | $158.6M | $42.86B | — | — | $1.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ULBI // BETA —
TMO // BETA 0.94